C4 Therapeutics Analyst Ratings
C4 Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | -38.65% | Morgan Stanley | $3 → $1 | Upgrades | Underweight → Equal-Weight |
| 11/03/2023 | 881.6% | BMO Capital | $18 → $16 | Maintains | Outperform |
| 11/02/2023 | 329.45% | HC Wainwright & Co. | $17 → $7 | Maintains | Buy |
| 10/09/2023 | 22.7% | B of A Securities | $5 → $2 | Maintains | Neutral |
| 08/09/2023 | 942.94% | HC Wainwright & Co. | $25 → $17 | Maintains | Buy |
| 05/30/2023 | 513.5% | Evercore ISI Group | $20 → $10 | Maintains | Outperform |
| 05/12/2023 | 84.05% | Morgan Stanley | $5 → $3 | Maintains | Underweight |
| 05/08/2023 | 1433.74% | HC Wainwright & Co. | $35 → $25 | Maintains | Buy |
| 03/28/2023 | 206.75% | B of A Securities | $11 → $5 | Maintains | Neutral |
| 02/27/2023 | 206.75% | Morgan Stanley | $6 → $5 | Maintains | Underweight |
| 02/24/2023 | 2047.24% | HC Wainwright & Co. | → $35 | Reiterates | → Buy |
| 02/24/2023 | 206.75% | JP Morgan | $15 → $5 | Downgrades | Neutral → Underweight |
| 01/03/2023 | 452.15% | Wells Fargo | $11 → $9 | Maintains | Equal-Weight |
| 11/08/2022 | 574.85% | Wells Fargo | $12 → $11 | Maintains | Equal-Weight |
| 11/04/2022 | 820.25% | JP Morgan | $22 → $15 | Downgrades | Overweight → Neutral |
| 10/11/2022 | 268.1% | Morgan Stanley | → $6 | Initiates Coverage On | → Underweight |
| 05/09/2022 | 2047.24% | HC Wainwright & Co. | $63 → $35 | Maintains | Buy |
| 04/28/2022 | 513.5% | Credit Suisse | → $10 | Initiates Coverage On | → Underperform |
| 04/18/2022 | 1495.09% | UBS | $64 → $26 | Maintains | Buy |
| 04/11/2022 | 1126.99% | BMO Capital | $57 → $20 | Maintains | Outperform |
| 03/10/2022 | 2538.04% | JP Morgan | → $43 | Initiates Coverage On | → Overweight |
| 02/10/2022 | 1433.74% | Wells Fargo | → $25 | Initiates Coverage On | → Equal-Weight |
| 11/23/2021 | 3212.88% | B of A Securities | → $54 | Initiates Coverage On | → Buy |
| 10/14/2021 | 4010.43% | SVB Leerink | → $67 | Initiates Coverage On | → Outperform |
| 09/30/2021 | 2660.74% | Stifel | → $45 | Initiates Coverage On | → Hold |
| 06/24/2021 | 3212.88% | Brookline Capital | → $54 | Initiates Coverage On | → Buy |
| 06/04/2021 | 3765.03% | HC Wainwright & Co. | → $63 | Initiates Coverage On | → Buy |
| 03/31/2021 | 3274.23% | BMO Capital | → $55 | Initiates Coverage On | → Outperform |
| 10/27/2020 | 1924.54% | BMO Capital | → $33 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/06/2023 | -38.65% | 摩根士丹利 | 3 美元 → 1 美元 | 升級 | 體重不足 → 重量相等 |
| 11/03/2023 | 881.6% | BMO Capital | 18 美元 → 16 美元 | 維護 | 跑贏大盤 |
| 11/02/2023 | 329.45% | HC Wainwright & Co. | 17 美元 → 7 美元 | 維護 | 購買 |
| 2023 年 9 月 10 日 | 22.7% | B of A 類證券 | 5 美元 → 2 美元 | 維護 | 中立 |
| 08/09/2023 | 942.94% | HC Wainwright & Co. | 25 美元 → 17 美元 | 維護 | 購買 |
| 05/30/2023 | 513.5% | Evercore ISI 集團 | 20 美元 → 10 美元 | 維護 | 跑贏大盤 |
| 05/12/2023 | 84.05% | 摩根士丹利 | 5 美元 → 3 美元 | 維護 | 體重不足 |
| 05/08/2023 | 1433.74% | HC Wainwright & Co. | 35 美元 → 25 美元 | 維護 | 購買 |
| 03/28/2023 | 206.75% | B of A 類證券 | 11 美元 → 5 美元 | 維護 | 中立 |
| 02/27/2023 | 206.75% | 摩根士丹利 | 6 美元 → 5 美元 | 維護 | 體重不足 |
| 02/24/2023 | 2047.24% | HC Wainwright & Co. | → 35 美元 | 重申 | → 購買 |
| 02/24/2023 | 206.75% | 摩根大通 | 15 美元 → 5 美元 | 降級 | 中性 → 體重不足 |
| 01/03/2023 | 452.15% | 富國銀行 | 11 美元 → 9 美元 | 維護 | 等重 |
| 2022 年 8 月 11 日 | 574.85% | 富國銀行 | 12 美元 → 11 美元 | 維護 | 等重 |
| 2022 年 4 月 11 日 | 820.25% | 摩根大通 | 22 美元 → 15 美元 | 降級 | 超重 → 中性 |
| 2022 年 10 月 11 日 | 268.1% | 摩根士丹利 | → 6 美元 | 啓動覆蓋範圍開啓 | → 體重不足 |
| 05/09/2022 | 2047.24% | HC Wainwright & Co. | 63 美元 → 35 美元 | 維護 | 購買 |
| 04/28/2022 | 513.5% | 瑞士信貸 | → 10 美元 | 啓動覆蓋範圍開啓 | → 表現不佳 |
| 04/18/2022 | 1495.09% | 瑞銀（UBS） | 64 美元 → 26 美元 | 維護 | 購買 |
| 2022 年 11 月 4 日 | 1126.99% | BMO Capital | 57 美元 → 20 美元 | 維護 | 跑贏大盤 |
| 03/10/2022 | 2538.04% | 摩根大通 | → 43 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 02/10/2022 | 1433.74% | 富國銀行 | → 25 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 11/23/2021 | 3212.88% | B of A 類證券 | → 54 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 10 月 14 日 | 4010.43% | SVB Leerink | → 67 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 09/30/2021 | 2660.74% | Stifel | → 45 美元 | 啓動覆蓋範圍開啓 | → 按住 |
| 2021 年 6 月 24 日 | 3212.88% | 布魯克林資本 | → 54 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/04/2021 | 3765.03% | HC Wainwright & Co. | → 63 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2021 年 3 月 31 日 | 3274.23% | BMO Capital | → 55 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 10/27/2020 | 1924.54% | BMO Capital | → 33 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for C4 Therapeutics (CCCC)?
C4 Therapeutics（CCCC）的目標價格是多少？
The latest price target for C4 Therapeutics (NASDAQ: CCCC) was reported by Morgan Stanley on November 6, 2023. The analyst firm set a price target for $1.00 expecting CCCC to fall to within 12 months (a possible -38.65% downside). 14 analyst firms have reported ratings in the last year.
摩根士丹利於2023年11月6日公佈了C4 Therapeutics（納斯達克股票代碼：CCCC）的最新目標股價。該分析公司將目標股價設定爲1.00美元，預計CCCC將在12個月內跌至1.00美元（可能下跌-38.65％）。去年有14家分析公司公佈了評級。
What is the most recent analyst rating for C4 Therapeutics (CCCC)?
C4 Therapeutics（CCCC）的最新分析師評級是多少？
The latest analyst rating for C4 Therapeutics (NASDAQ: CCCC) was provided by Morgan Stanley, and C4 Therapeutics upgraded their equal-weight rating.
C4 Therapeutics（納斯達克股票代碼：CCCC）的最新分析師評級由摩根士丹利提供，C4 Therapeutics上調了同等權重評級。
When is the next analyst rating going to be posted or updated for C4 Therapeutics (CCCC)?
C4 Therapeutics（CCCC）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of C4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for C4 Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與C4 Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。C4 Therapeutics的最後一次評級是在2023年11月6日提交的，因此您應該預計下一個評級將在2024年11月6日左右公佈。
Is the Analyst Rating C4 Therapeutics (CCCC) correct?
分析師評級C4 Therapeutics（CCCC）是否正確？
While ratings are subjective and will change, the latest C4 Therapeutics (CCCC) rating was a upgraded with a price target of $3.00 to $1.00. The current price C4 Therapeutics (CCCC) is trading at is $1.63, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的C4 Therapeutics（CCCC）評級已上調，目標股價爲3.00美元至1.00美元。C4 Therapeutics（CCCC）目前的交易價格爲1.63美元，超出了分析師的預測區間。